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I
nternational health agencies have 
designated a group of 13 tropical 
infections as neglected diseases 
(Text S1). These diseases have much 
in common: they affect the world’s 
poorest people (and are a cause of 
poverty); they are disabling, disﬁ  guring, 
and stigmatizing; there is a shortage 
of safe and effective treatments; and 
affected patients have represented the 
lowest-priority markets for Western 
pharmaceutical manufacturers. Bernard 
Pécoul of the Drugs for Neglected 
Diseases Initiative (DNDi) has called 
these patients “the forgotten people.”
The conventional wisdom is that the 
outlook for such patients is hopeless. As 
one of us has argued, “[They] have no 
purchasing power, no vocal advocacy 
group is pleading for their needs, 
and no strategic interests—military or 
security—are driving concern about 
these conditions” (BMJ 325: 176–177). 
Hence, only 13 new drugs have been 
developed for neglected tropical 
diseases since 1975, and they have 
garnered little international attention 
compared with “the big three” global 
health threats: HIV/AIDS, tuberculosis, 
and malaria.
Fortunately, there is good news 
to report. The “2005 reality,” argues 
Mary Moran of the London School of 
Economics in an article in PLoS Medicine 
(DOI: 10.1371/journal.pmed.0020302), 
is that an explosion of public–private 
partnerships for health has dramatically 
altered the landscape of neglected-
disease drug development. Her analysis 
shatters a common illusion—that 
industry is profoundly disinterested in 
developing drugs for neglected diseases. 
“Long-held beliefs on neglected-disease 
drug development activity are no longer 
accurate,” writes Moran.
According to her analysis, 63 
neglected-disease drug projects 
were under way at the end of 2004. 
Three-quarters are being conducted 
by public–private partnerships that 
often involve multinational or small-
scale commercial ﬁ  rms. Twenty new 
products are already in clinical trials, 
including half at the phase III or 
registration stage. Assuming there 
is sufﬁ  cient funding, at standard 
attrition rates these projects would be 
expected to deliver eight or nine new 
neglected-disease drugs within the 
next ﬁ  ve years. “The post-2000 renewal 
of neglected-disease R&D activity is 
good news for patients with neglected 
diseases,” writes Moran.
There are even more reasons for 
optimism. Firstly, many countries 
affected by neglected diseases, such 
as Brazil, Egypt, and India, now have 
the infrastructure to conduct their 
own neglected-disease research. Morel 
and colleagues have called these the 
“innovative developing countries” 
(Science 309: 401–404), and say they are 
now reaping the beneﬁ  ts of decades of 
investment in education, health research 
infrastructure, and manufacturing 
capacity. These countries can begin 
controlling their endemic tropical 
diseases themselves by developing their 
own treatments and vaccines with only 
modest technical or ﬁ  nancial assistance 
from more developed countries. 
Secondly, in addition to the 
expectation that new tools will be 
developed to control neglected diseases, 
there is a surge of interest in maximizing 
the effectiveness of existing tools. This 
interest focuses on the idea of taking the 
disparate vertical control programs, each 
targeting a speciﬁ  c neglected disease, 
and delivering them in one integrated 
package. For example, important work 
is under way to examine the impact of 
four drugs—albendazole, praziquantel, 
azithromycin, and ivermectin—in a 
single delivery mechanism in order 
to simultaneously target lymphatic 
ﬁ  lariasis, onchocerciasis, soil-transmitted 
helminthiases, schistosomiasis, and 
trachoma (Lancet 365: 1029–1030).
Thirdly, and perhaps most 
importantly, the neglected diseases 
have at long last caught the attention 
of the international development 
community. The penny has ﬁ  nally 
dropped: neglected-disease control 
will be crucially important to achieving 
many of the Millenium Development 
Goals, and investment into neglected 
diseases must become a priority 
for donors. On June 8, 2005, DNDi 
launched an appeal, signed by 17 
Nobel laureates among others, calling 
on donors to create a new fund of $3 
billion a year for neglected-disease 
R&D (http:⁄⁄www.researchappeal.
org), while the Commission for Africa 
urged donors to “ensure that there is 
adequate funding for the treatment 
and prevention of parasitic diseases.” 
It is therefore encouraging that the 
Gleneagles Communiqué, arising out 
of this year’s G8 summit, speciﬁ  cally 
called for increased investment to 
encourage the development of tools 
for neglected-disease control. Another 
sign that donors are taking notice is 
that the US Senate recently passed a 
foreign operations appropriations bill 
that included $30 million for neglected 
diseases. This successful appropriation 
was in large part due to the advocacy of 
the Global Health Council, Eric Otteson 
at Emory University, and Peter Hotez at 
George Washington University.
There is one element that will 
be crucial to the success of all of 
these new initiatives—the ability to 
share research results and policy 
discussions freely across the globe, 
without access barriers. PLoS Biology 
and PLoS Medicine are committed to 
publishing the highest-quality basic 
and clinical research on neglected 
diseases, and PLoS is exploring the 
feasibility of launching a new journal 
devoted speciﬁ  cally to these diseases. 
The “2005 reality” is that there is an 
unprecedented window of opportunity 
for neglected-disease control, and PLoS 
will play its part.  
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